← Human Trials & Peer-Reviewed Studies
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
Plain-language guide to PMID 10852440 (2000): double-blind randomized controlled trial study of Teriparatide and Parathyroid Hormone (PTH 1-84), osteoporosis and bone density.
Key Facts
- PMID
- 10852440
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2000
- Study type
- Randomized Controlled Trial
- Authors
- Rittmaster RS et al. (7 authors)
- DOI
- 10.1210/jcem.85.6.6614
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Teriparatide and Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density.
The purpose of the present study was to determine whether the bisphosphonate alendronate could preserve or enhance bone density in patients previously treated with PTH.
Why It Was Studied
However, this effect is rapidly reversed when the treatment is stopped.
Markers of bone turnover included skeletal alkaline phosphatase, osteocalcin, and N-telopeptide.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Teriparatide, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Teriparatide could be set against what happens without it.
BMD was measured in the femoral neck, lumbar spine, and whole body.
What Was Measured
Topics PubMed links to this paper include Alendronate, Alkaline Phosphatase, Biomarkers, Bone Density, Collagen, Collagen Type I and Femur.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Teriparatide and Parathyroid Hormone (PTH 1-84) in people with osteoporosis and bone density.
The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.
Our Notes on the Compounds
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
- Osteoporosis and bone density research
- Teriparatide in the library
- Parathyroid Hormone (PTH 1-84) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.